TW202241946A - 針對整合素α１１β１之抗體 - Google Patents

針對整合素α１１β１之抗體 Download PDF

Info

Publication number
TW202241946A
TW202241946A TW110147384A TW110147384A TW202241946A TW 202241946 A TW202241946 A TW 202241946A TW 110147384 A TW110147384 A TW 110147384A TW 110147384 A TW110147384 A TW 110147384A TW 202241946 A TW202241946 A TW 202241946A
Authority
TW
Taiwan
Prior art keywords
seq
antibody
light chain
antigen
heavy chain
Prior art date
Application number
TW110147384A
Other languages
English (en)
Chinese (zh)
Inventor
艾爾瑪 庫爾塔吉克
詹姆士 梅多爾
克里斯托弗 貝杜斯
Original Assignee
美商健生生物科技公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商健生生物科技公司 filed Critical 美商健生生物科技公司
Publication of TW202241946A publication Critical patent/TW202241946A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW110147384A 2020-12-18 2021-12-17 針對整合素α１１β１之抗體 TW202241946A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063127849P 2020-12-18 2020-12-18
US63/127,849 2020-12-18
US202163213973P 2021-06-23 2021-06-23
US63/213,973 2021-06-23

Publications (1)

Publication Number Publication Date
TW202241946A true TW202241946A (zh) 2022-11-01

Family

ID=79021748

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110147384A TW202241946A (zh) 2020-12-18 2021-12-17 針對整合素α１１β１之抗體

Country Status (13)

Country Link
US (1) US20240317865A1 (https=)
EP (1) EP4263605A2 (https=)
JP (1) JP2024505790A (https=)
KR (1) KR20230121831A (https=)
AU (1) AU2021400221A1 (https=)
BR (1) BR112023011777A2 (https=)
CA (1) CA3205574A1 (https=)
CL (1) CL2023001757A1 (https=)
CO (1) CO2023008544A2 (https=)
IL (1) IL303741A (https=)
MX (1) MX2023007302A (https=)
TW (1) TW202241946A (https=)
WO (1) WO2022130318A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021127500A1 (en) 2019-12-20 2021-06-24 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79289A (en) 1985-07-05 1992-01-15 Whitehead Biomedical Inst Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
ATE117375T1 (de) 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
WO1989007136A2 (en) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2096750T3 (es) 1990-10-31 1997-03-16 Somatix Therapy Corp Vectores retroviricos utiles para la terapia genica.
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
WO2003022330A2 (en) 2001-09-12 2003-03-20 Becton, Dickinson And Company Microneedle-based pen device for drug delivery and method for using same
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
EP3524625A1 (en) * 2018-02-08 2019-08-14 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
EP3760722A4 (en) * 2018-03-01 2021-11-24 Hiroshima University MONOCLONAL ANTI-INTEGRIN ALPHA11 ANTIBODY AND USES THEREOF
WO2021127500A1 (en) * 2019-12-20 2021-06-24 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1

Also Published As

Publication number Publication date
AU2021400221A1 (en) 2023-07-13
MX2023007302A (es) 2023-09-04
US20240317865A1 (en) 2024-09-26
KR20230121831A (ko) 2023-08-21
AU2021400221A9 (en) 2025-03-13
WO2022130318A3 (en) 2022-08-04
EP4263605A2 (en) 2023-10-25
BR112023011777A2 (pt) 2023-10-03
CL2023001757A1 (es) 2024-01-05
CA3205574A1 (en) 2022-06-23
WO2022130318A2 (en) 2022-06-23
IL303741A (en) 2023-08-01
CO2023008544A2 (es) 2023-07-10
JP2024505790A (ja) 2024-02-08

Similar Documents

Publication Publication Date Title
JP5896993B2 (ja) ヒトｇｄｆ８に対する抗体
JP6367233B2 (ja) 抗ｐｄｇｆｒ−ベータ抗体及びそれらの使用
US20260042845A1 (en) Antibodies against integrin alpha 11 beta 1
JP2020520912A (ja) 抗ｇｉｔｒアゴニスト抗体での癌の処置
JP2024518776A (ja) 抗ａｄｇｒｅ２抗体及びその使用
TW202241944A (zh) 新穎的抗ｇｒｅｍｌｉｎ１抗體
TW201735949A (zh) 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
US12600784B2 (en) Anti-Clec12A antibodies and uses thereof
TW202241946A (zh) 針對整合素α１１β１之抗體
KR20190044094A (ko) 투여량 레지멘
EA048635B1 (ru) Антитела против интегрина альфа 11 бета 1
JP7769635B2 (ja) 抗ｃｄ１９抗体及びその使用
CN117222666A (zh) 抗整联蛋白α11β1抗体
JP2025523477A (ja) インテグリンアルファ１１ベータ１に対する抗体及びその使用
TW202511292A (zh) 用於治療ＮＳＣＬＣ及ｃＨＬ之ＰＤ－１／ＴＩＭ－３結合蛋白
EA051556B1 (ru) Антитела к adgre2 и их применение
EP3694877A1 (en) Anti-il-33 therapy for atopic dermatitis